Hims & Hers under fire over copycat weight loss drugs
Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs. Federal regulators are seeking to rein in the online telemedicine platform, which for years has been selling a non-Food and Drug Administration (FDA) approved version of GLP-1 medication semaglutide even though it is…
Related Posts
Morning Minute: Coinbase Reports $667 Million Loss Amid Bitcoin Dive
Morning Minute is a daily newsletter written by
Coinbase Reports Q4 Miss With $667 Million Loss Amid Bitcoin Retreat
Coinbase disclosed $1.78 billion in fourth-quarter rev...
Coinbase swings to surprise loss amid crypto exodus, but says traders are buying the dip
The crypto exchange’s stock bounced off a two-year low as it looked to ease investor worries amid a sharp crypto selloff.
GFN Thursday: GeForce NOW on Amazon Fire TV
The GeForce NOW sixth-anniversary festivities roll on...
It’s still a ‘low fire’ jobs market. Jobless claims stay low and unemployment falls early in the new year.
Businesses aren’t hiring much, but they’re not resorting to big layoffs, either
Fire risk report on Kidlington illegal waste tip kept from public
Baroness Sheehan, who is due to raise the issue in a Lords debate on Thursday, called for the report into the 21,000-tonne site to...
Legal pressures mount for Hims & Hers over GLP-1 sales
Presented by the Coalition to Strengthen America's Healthcare {beacon} Health Care Health Care The Big Story Legal pressures mount for...
‘Guests tell me I have dust bunnies’: My $150-an-hour cleaner has become increasingly negligent. Do I fire her?
”I like her as a friend, but I’m underwhelmed as a client.”
